Share chart Jazz Pharmaceuticals plc
Extended chart
Simple chart
About
Jazz Pharmaceuticals plc, биофармацевтическая компания, выявляет, разрабатывает и продает фармацевтические продукты для различных неудовлетворенных медицинских потребностей в США, Европе и за рубежом. У компании есть портфель продуктов и продуктов-кандидатов с акцентом на области нейробиологии, включая медицину сна и двигательные расстройства; и в онкологии, включая гематологические и солидные опухоли.
More detailsP/E | 16.06 |
---|---|
P/S | 3.89 |
P/BV | 2.7 |
EV/EBITDA | 9.56 |
EBITDA | 0.9972 |
Цена ао | 108.05 |
Сайт | http://www.jazzpharma.com |
Число акций ао | 0.07207 млрд |
Выручка | 2.16 |
Див.доход ао | 0 |
ISIN | IE00B4Q5ZN47 |
Валюта | usd |
IPO date | 2007-06-01 |
Sector | Health Care |
Industry | Pharmaceuticals |
Валюта отчета | usd |
Change price per day: | -7.87% (117.28) |
---|---|
Change price per week: | +0.6802% (107.32) |
Change price per month: | -1.39% (109.57) |
Change price per 3 month: | -0.7258% (108.84) |
Change price per half year: | -1.72% (109.94) |
Change price per year: | -18.5% (132.58) |
Change price per 3 year: | -19.3% (133.89) |
Change price per 5 year: | -9.69% (119.65) |
Change price per year to date: | -10.96% (121.35) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Transaction date | Date of disclosure | Insider | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
---|---|---|---|---|---|---|---|---|---|
06.08.2024 | 05.08.2024 | Cook Jennifer E. Director |
Purchase | 111 | 341 325 | 3075 | 0 | 0.01 | link |
06.08.2024 | 05.08.2024 | McSharry Heather Ann Director |
Purchase | 111 | 341 325 | 3075 | 0 | 0.01 | link |
06.08.2024 | 05.08.2024 | O'Keefe Kenneth W Director |
Purchase | 111 | 341 325 | 3075 | 0 | 0.01 | link |
06.08.2024 | 05.08.2024 | ORiordan Anne Director |
Purchase | 111 | 341 325 | 3075 | 0 | 0.01 | link |
06.08.2024 | 05.08.2024 | RIEDEL NORBERT G Director |
Purchase | 111 | 341 325 | 3075 | 0 | 0.01 | link |
06.08.2024 | 05.08.2024 | Smith Mark Douglas Director |
Purchase | 111 | 341 325 | 3075 | 0 | 0.01 | link |
07.06.2024 | 11.06.2024 | Carr Patricia SVP, Chief Accounting Officer |
Sale | 108.83 | 17 739 | 163 | 0 | 0 | link |
07.03.2024 | 08.03.2024 | Carr Patricia SVP, Chief Accounting Officer |
Sale | 116.98 | 206 821 | 1768 | 0 | 0 | link |
06.03.2024 | 08.03.2024 | Carr Patricia SVP, Chief Accounting Officer |
Sale | 119.64 | 231 623 | 1936 | 0 | 0 | link |
14.08.2023 | 15.08.2023 | O'Keefe Kenneth W Director |
Sale | 138.16 | 171 457 | 1241 | 0 | 0 | link |
14.08.2023 | 15.08.2023 | ORiordan Anne Director |
Sale | 138.16 | 171 457 | 1241 | 0 | 0 | link |
08.03.2023 | 10.03.2023 | Sablich Kim EVP, GM of U.S., Commercial Ma |
Sale | 139.74 | 421 037 | 3013 | 0 | 0 | link |
05.12.2022 | 07.12.2022 | Carr Patricia SVP, Chief Accounting Officer |
Sale | 152.06 | 9 580 | 63 | 0 | 0 | link |
22.11.2022 | 25.11.2022 | ENRIGHT PATRICK G Director |
Sale | 152.88 | 305 760 | 2000 | 0 | 0 | link |
22.11.2022 | 25.11.2022 | ENRIGHT PATRICK G Director |
Sale | 149.48 | 743 514 | 4974 | 0 | -0.01 | link |
14.11.2022 | 16.11.2022 | Larkin Finbar SVP, Technical Operations |
Sale | 149.33 | 29 418 | 197 | 0 | 0 | link |
10.11.2022 | 14.11.2022 | Pearce Samantha SVP, Head of Europe & Internat |
Purchase | 109.45 | 116 345 | 1063 | 0 | 0 | link |
10.11.2022 | 14.11.2022 | Pearce Samantha SVP, Head of Europe & Internat |
Sale | 155 | 164 765 | 1063 | 0 | 0 | link |
12.07.2022 | 14.07.2022 | Pearce Samantha SVP, Head of Europe & Internat |
Sale | 155 | 82 460 | 532 | 0 | 0 | link |
12.07.2022 | 14.07.2022 | Pearce Samantha SVP, Head of Europe & Internat |
Purchase | 109.45 | 58 227 | 532 | 0 | 0 | link |
11.05.2022 | 11.05.2022 | Carr Patricia SVP, Chief Accounting Officer |
Sale | 147.51 | 106 502 | 722 | 0 | 0 | link |
10.05.2022 | 11.05.2022 | Carr Patricia SVP, Chief Accounting Officer |
Sale | 144.18 | 39 361 | 273 | 0 | 0 | link |
09.05.2022 | 11.05.2022 | Carr Patricia SVP, Chief Accounting Officer |
Sale | 148.94 | 158 919 | 1067 | 0 | 0 | link |
Institutions | Volume | Share, % |
---|---|---|
Blackrock Inc. | 7056032 | 11.2 |
Vanguard Group Inc | 6363748 | 10.1 |
State Street Corporation | 2421125 | 3.84 |
LSV Asset Management | 2343227 | 3.72 |
JP Morgan Chase & Company | 1397284 | 2.22 |
Ameriprise Financial, Inc. | 1312771 | 2.08 |
Wellington Management Group, LLP | 1280197 | 2.03 |
Polaris Capital Management Inc | 1267460 | 2.01 |
Renaissance Technologies, LLC | 1231574 | 1.95 |
FMR, LLC | 1228991 | 1.95 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Mr. Bruce C. Cozadd | Co-Founder, Chairman & CEO | 2.45M | 1964 (60 years) |
Ms. Renee D. Gala | President & COO | 1972 (52 years) | |
Ms. Patricia Carr | Senior VP & Chief Accounting Officer | 1971 (53 years) | |
Ms. Neena M. Patil J.D. | Executive VP & Chief Legal Officer | 1975 (49 years) | |
Mr. Philip L. Johnson | Executive VP & CFO | 1964 (60 years) | |
Ms. Andrea N. Flynn Ph.D. | VP & Head of Investor Relations | ||
Ms. Heidi Manna | Executive VP & Chief People Officer | 1971 (53 years) | |
Dr. Jed Black M.D. | Senior Vice President of Sleep & CNS Medicine | ||
Ms. Samantha Pearce | Executive VP & Chief Commercial OfficerChief Commercial Officer | 1966 (58 years) | |
Dr. Robert Iannone M.D. | Executive VP, Chief Medical Officer and Global Head of Research & Development | 1967 (57 years) |
Address: Ireland, Dublin , Waterloo Exchange - open in Google maps, open in Yandex maps
Website: http://www.jazzpharma.com
Website: http://www.jazzpharma.com